Table 1.
Clinical record of the patient during treatment
| Date | Infectious indicators | Treatment | Body temperature (highest) |
|---|---|---|---|
| 7.10 | WBC: 19.83 * 10^9/L ↑ GR: 85% ↑ CRP: 108.3 mg/L ↑ PCT: 0.056 ng/mL | Before hospitalization | 40.0 °C |
| 7.20 | WBC: 30.13 * 10^9/L ↑ GR: 86.1% ↑ CRP: 72.67 mg/L ↑ PCT: 2.25ug/L ↑ | Vancomycin | 40.3 °C |
| 7.21 | CEA: 8.68 ng/mL ↑ SCC: 3.10 ng/mL ↑ CYFRA21_1: 6.37 ng/mL ↑ | ||
| 7.23 | WBC: 30.64 * 10^9/L ↑ GR: 90.3% ↑ CRP: 149.24 mg/L ↑ | + Voricanozole | |
| 7.24 | Metagenomic Next-Generation Sequencing result indicated tumour, clinicians performed lung puncture | Meropenem | 40.0 °C |
| 7.28 | WBC: 19.37 * 10^9/L ↑ GR: 85.9% ↑ CRP: 153.02 mg/L ↑ | + Voriconazole | |
| Report of lung puncture showed tumor, SLC was considered | |||
| 7.29 | CEA: 9.59 ng/mL ↑ SCC: 4.3 ng/mL ↑ | 37.5 °C | |
| 7.30 | Operation (radical resection of lung cancer) | ||
| 7.31 |
WBC: 9.62 * 10^9/L ↑ GR: 76.9% ↑ CRP: 124.36 mg/L ↑ PCT: 0.35%↑ |
Cefoperazone sodium sulbactam | |
| 8.13 | Discharged from hospital | ||
| 9.8 |
WBC: 7.19 * 10^9/L GR: 57.3% CRP: 20.1 mg/L ↑ PCT: 0.22% CEA: 1.84 ng/mL SCC: 0.4 ng/mL CYFRA21_1: 1.9 ng/mL |
Normal (< 37 °C) | |
WBC white blood cell, GR granulocytes, CRP C-reactive protein, PCT plateletcrit, CEA carcinoembryonic antigen, SCC squamous cell carcinoma, CYFRA21_1 cytokeratin-19 fragment
“↑” indicates higher than normal range